Massive 3,000-Patient study tracks Real-Life impact of new breast cancer drugs
NCT ID NCT07243002
Summary
This study is observing 3,000 people with stage II or III breast cancer who are already taking either ribociclib or abemaciclib along with hormone therapy. Researchers will look at medical records and ask patients about their experiences to understand how well the drugs work to keep cancer from returning, what side effects occur, and how treatment affects daily life and work. The goal is to learn how these medications perform in everyday clinical practice outside of controlled trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGLondon, SW3 6JJ, United Kingdom
Conditions
Explore the condition pages connected to this study.